Doxycycline |
Catalog No.GC63621
One-Click Copy Product Info
|
Doxycycline is a tetracycline-derivative wide-spectrum antibiotic, inhibit protein synthesis by interfering with the binding of activated aminoacyl-tRNAs on the A-site of the 30S subunit of bacterial ribosomes.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 564-25-0
Sample solution is provided at 25 µL, 10mM.
Doxycycline is a tetracycline-derivative wide-spectrum antibiotic, inhibit protein synthesis by interfering with the binding of activated aminoacyl-tRNAs on the A-site of the 30S subunit of bacterial ribosomes. It is used to treat a variety of infections caused by bacteria and protozoa. Doxycycline is also a nonspecific matrix metalloproteinase (MMP) inhibitor. Doxycycline exhibits anti-tumour and pro-apoptotic activity [1-4].
Doxycycline(0-250 µM; 72h) inhibits cell viability of breast cancer cells and mammospheres[5]. Doxycycline (100 ng/mL, 1 µg/mL; 24 h) reduces proliferation of human cell lines[6].
Doxycycline(20mg /kg; p.o.;2times) treated following mice TBI improved behavioral and motor function suggesting doxycycline's role in preserving murine BBB integrity[7]. Doxycycline(DOX in drinking water (6 mg/ml, 5 ml/day/mice) ; 36 days) significantly minimized the dystrophic phenotype of skeletal and cardiac muscles and improved forelimb muscle strength[8]. The FM(fecal microbiota) of female C57BL/6NCrl mice is significantly altered by administration of doxycycline(doxycycline in the drinking water at 2 mg/ml during weeks 1, 2, and 4) at a concentration of 2 mg/ml in the drinking water[9].
References:
[1]. Cunha BA, Sibley CM, et,al. Doxycycline. Ther Drug Monit. 1982;4(2):115-35. doi: 10.1097/00007691-198206000-00001. PMID: 7048645.
[2].Manchado E, Weissmueller S, et,al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016 Jun 30;534(7609):647-51. doi: 10.1038/nature18600. Epub 2016 Jun 22. PMID: 27338794; PMCID: PMC4939262.
[3].Luger AL, Sauer B, et,al. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. Int J Mol Sci. 2018 May 17;19(5):1504. doi: 10.3390/ijms19051504. PMID: 29772845; PMCID: PMC5983704.
[4]. Duivenvoorden WC, Popović SV, et,al. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Res. 2002 Mar 15;62(6):1588-91. PMID: 11912125.
[5]. Zhang L, Xu L, et,al. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017 Apr 18;16(8):737-745. doi: 10.1080/15384101.2016.1241929. Epub 2016 Oct 18. PMID: 27753527; PMCID: PMC5405729.
[6]. Ahler E, Sullivan WJ, et,al. Doxycycline alters metabolism and proliferation of human cell lines. PLoS One. 2013 May 31;8(5):e64561. doi: 10.1371/journal.pone.0064561. PMID: 23741339; PMCID: PMC3669316.
[7]. Malek AJ, Robinson BD, et,al. Doxycycline improves traumatic brain injury outcomes in a murine survival model. J Trauma Acute Care Surg. 2020 Sep;89(3):435-440. doi: 10.1097/TA.0000000000002801. PMID: 32467458.
[8]. Pereira JA, Taniguti AP, et,al. Doxycycline ameliorates the dystrophic phenotype of skeletal and cardiac muscles in mdx mice. Muscle Nerve. 2012 Sep;46(3):400-6. doi: 10.1002/mus.23331. PMID: 22907231.
[9]. Boynton FDD, Ericsson AC, et,al. Doxycycline induces dysbiosis in female C57BL/6NCrl mice. BMC Res Notes. 2017 Nov 29;10(1):644. doi: 10.1186/s13104-017-2960-7. PMID: 29187243; PMCID: PMC5708113.
| Cell experiment [1]: | |
|
Cell lines |
MCF-7 and MDA-MB-468 cells |
|
Preparation Method |
Cells were seeded in 96-well plates at a density of 5000 cells/well. The cells were incubated with doxycycline at concentrations of 0-250 µM for 72 hours. |
|
Reaction Conditions |
0-250 µM; 72h |
|
Applications |
Doxycycline inhibits cell viability of breast cancer cells and mammospheres. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6J mice |
|
Preparation Method |
Mice were assigned to a sham, Traumatic brain injury (TBI), or TBI with doxycycline arm. A moderate TBI was induced utilizing a controlled cortical impactor. The TBI with doxycycline cohort received a dose of doxycycline (20 mg/kg) 2 hours after injury and every 12 hours until postoperative day (POD) 6. |
|
Dosage form |
20 mg/kg; p.o ; 2 times |
|
Applications |
Doxycycline treated following mice TBI improved behavioral and motor function. |
|
References: [1]. Zhang L, Xu L, et,al. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017 Apr 18;16(8):737-745. doi: 10.1080/15384101.2016.1241929. Epub 2016 Oct 18. PMID: 27753527; PMCID: PMC5405729. |
|
| Cas No. | 564-25-0 | SDF | |
| Formula | C22H24N2O8 | M.Wt | 444.43 |
| Solubility | DMSO : 125 mg/mL (281.26 mM; Need ultrasonic) | Storage | Store at 4°C, protect from light, stored under argon |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2501 mL | 11.2504 mL | 22.5007 mL |
| 5 mM | 450 μL | 2.2501 mL | 4.5001 mL |
| 10 mM | 225 μL | 1.125 mL | 2.2501 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)